Partners

Investors

AFM

AFM has shown a long-lasting support to Pr. Olivier Pourquié’s laboratory in the first place and then to Anagenesis Biotechnologies:

  • Funding of a strategic research project (2009-2013)
  • Partner of Pr. Olivier Pourquié laboratory and Anagenesis Biotechnologies for the MYOSTEM collaborative research program (2013-2015)
  • Anagenesis Biotechnologies capital increase
CIE-Logo

Cap Innov'Est (CIE) has invested in Anagenesis Biotechnologies in April 2015 and in November 2018

Cap Innov’Est is a 45 M€ regional (G rand-Est, Bourgogne-Franche-Comté) fund dedicated to investments in young innovative start-ups. Cap Innov’Est was launched in July 2014 and has already invested in 22 start-ups. Cap Innov’Est is managed by Capital Grand Est in partnership with Invest PME (Siparx group). Cap Innov’Est is supported by Fonds National d’Amorçage, the Regions Grand-Est and Bourgogne-Franche-Comté, SAFIDI, Caisses d’Epargne d’Alsace et Bourgogne/Franche-Comté, BNP Paribas & CIFC.

For more informations, please visit: www.capitalgrandest.eu
BIVF

Boehringer Ingelheim Venture Fund (BIVF) has invested in Anagenesis Biotechnologies in November 2018

Created in 2010, the Boehringer Ingelheim Venture Fund GmbH (BIVF) invests in groundbreaking therapeutics-focused biotechnology companies to drive innovation in biomedical research. BIVF is searching for significant enhancements in patient care through pioneering science and its clinical translation by building long-term relationships with scientists and entrepreneurs. BIVF’s focus is to target unprecedented therapeutic concepts addressing high medical needs in immuno-oncology, in regenerative medicine or infectious diseases. These may include novel platform technologies to address so far undrugable targets, new generation vaccines and/or new biological entities, such as oncolytic virotherapy as well as Digital Health.

BIVF takes an active role with its portfolio companies – delivering significant added value through its own extensive drug discovery, scientific and managerial expertise. BIVF has € 250 million under management and currently supervises a portfolio of 25 companies.

For more information, please visit www.boehringer-ingelheim-venture.com

 

Supporting us

 
Region_Grand_Est Alsace biovalley AFM
bpi semia CIE-Logo
Strasbourg_eurometropole LOGO_EUROPTIMIST BIVF